Athens 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings
ATHENS escrs

Corneal visual rehabilitation in patients with phakic IOL related endothelial decompensation: clinical outcomes

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Session Details

Session Title: Cornea
Session Date/Time: Sunday 28/02/2016 | 08:30-11:00
Paper Time: 10:06
Venue: MC2 Room
First Author: : S.Crisostomo PORTUGAL
Co Author(s): :    N. Alves   J. Feijao   P. Candelaria   V. Maduro     

Abstract Details

Purpose:

To evaluate the clinical outcomes of phakic intraocular lens (phakic IOL) explantation, phacoemulsification, posterior chamber intraocular lens (PCIOL) implantation followed by Descemet stripping automated endothelial keratoplasty (DSAEK) performed for phakic IOL-related endothelial decompensation.

Setting:

Ophthalmology Department - Centro Hospitalar Lisboa Central - CHLC. Sara Crisóstomo; Nuno Alves; João Feijão; Pedro Candelária; Vitor Maduro.

Methods:

Retrospective case series of 16 eyes (8 patients) who developed endothelial decompensation after phakic IOL implantation. All patientes were treated with phakic IOL explantation, phacoemulsification, PCIOL implantation followed by DSAEK. Main outcome variables were best corrected visual acuity (BCVA), spherical equivalent, endothelial cell count, and intraoperative and postoperative complications.

Results:

16 eyes of 8 patients with 50.2 ±9.2 years old mean age. 14 eyes with Icare phakic anterior chamber IOL and 2 eyes with Nuvita phakic anterior chamber IOL. Mean follow up period was 24 months. All patients had improved mean BCVA after 12 months (from 20/100 to 20/30). Mean postoperative spherical equivalent was -3.1 ± 1.4 diopters. Mean endothelial cell loss in comparison to preoperative donor endothelial cell density was 24.3% ± 8.9%. There was 1 primary graft failure.

Conclusions:

This quadruple procedure can provide a fast and safe visual rehabilitation with good graft survival with minimal complications.

Financial Disclosure:

NONE

Back to previous